Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-03
2006-10-03
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S322000
Reexamination Certificate
active
07115564
ABSTRACT:
The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.
REFERENCES:
patent: 4195079 (1980-03-01), Celmer et al.
patent: 4239751 (1980-12-01), Coronelli et al.
patent: 4542018 (1985-09-01), Borghi et al.
patent: 4661470 (1987-04-01), Malabarba et al.
patent: 4782042 (1988-11-01), Selva et al.
patent: 4868171 (1989-09-01), Selva et al.
patent: 4882313 (1989-11-01), Sitrin
patent: 4914187 (1990-04-01), Malabarba et al.
patent: 4935238 (1990-06-01), Selva et al.
patent: 4954483 (1990-09-01), Malabarba et al.
patent: 5030619 (1991-07-01), Hector
patent: 5064811 (1991-11-01), Borghi et al.
patent: 5606036 (1997-02-01), Hermann et al.
patent: 5750509 (1998-05-01), Malabarba et al.
patent: 5843679 (1998-12-01), Selva et al.
patent: 5882900 (1999-03-01), Rizzo et al.
patent: 5891869 (1999-04-01), Lociuro et al.
patent: 5925550 (1999-07-01), Lancini et al.
patent: 5935238 (1999-08-01), Talcott et al.
patent: 6008225 (1999-12-01), Lociuro et al.
patent: 6143739 (2000-11-01), Lociuro et al.
patent: 6218505 (2001-04-01), Panzone et al.
patent: 6384013 (2002-05-01), Burkhardt et al.
patent: 6541616 (2003-04-01), Tucker et al.
patent: 0 071 970 (1983-02-01), None
patent: 0 095 154 (1983-11-01), None
patent: 0 177 882 (1986-04-01), None
patent: 0 204 179 (1986-12-01), None
patent: 0 228 015 (1987-07-01), None
patent: 0 240 609 (1987-10-01), None
patent: 0 259 781 (1988-03-01), None
patent: 0 301 785 (1989-02-01), None
patent: 0 316 712 (1989-05-01), None
patent: 0 376 041 (1990-07-01), None
patent: 0 525 499 (1993-02-01), None
patent: 0 801 075 (1997-10-01), None
patent: 0 931 834 (1999-07-01), None
patent: 2 121 401 (1983-12-01), None
patent: 2 142 234 (1984-02-01), None
patent: 1050900 (1989-02-01), None
patent: WO 88/02755 (1988-04-01), None
patent: WO 90/11300 (1990-10-01), None
A. Malabarba et al, “Glycopeptide derivatives”, Current Medicinal Chemistry, vol. 8, 2001, pp. 1759-1773.
T. Staroske et al, “Synthesis of covalent head-to-tail dimers of vancomycin”, Tetrahedron Letters, vol. 39, 1998, pp. 4917-4920.
G. Candiani et al., “In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic”, Journal of Antimicrobial Chemotherapy, vol. 44, 1999.
Dowell, et al. (2003). “Dalbavancin Dosage Adjustments Not Required for Patients with Mild Renal Impairment,” 2003 ECCMID Meeting.
Stogniew et al. (2003). “Pharmacokinetic Attributes of Dalbavancin: Well Distributed and Completely Eliminated With Dual Routes of Elimination,” 2003 ECCMID Meeting.
White et al. (2000). “V-Glycopeptide: Phase 1 Single and Mulltiple-dose Placebo Controlled Intravenous Safety, Pharmacokinetic, and Pharmacodynamic Study in Healthy Subjects,” Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep. 2000, p. 233.
Abramson, M.A. and Sexton, D.J. (1999). “Nosocomial Methicillin-Resistant and Methicillin-SusceptibleStaphylococcus AureusPrimary Bacteremia: At What Costs?”Infect. Control Hosp. Epidemiol. 20(6): 408-411.
Adamczyk, M. et al. (1999). “Investigations Into Self-Association of Vancornycin Covalent Dimers Using Surface Plasmon Resonance Technology,”Bioorganic&Medicinal Chemistry Letters9:2437-2440.
Ahrendt, K.A. et al. (2003). “Identification of Potent and Broad-Spectrum Antibiotics from SAR Studies of a Synthetic Vancomycin Analogue,”Bioorganic&Medicinal Chemistry Letters13:1683-1686.
Allen, N.E. and Nicas, T.I. (2003). “Mechanism of Action of Oritavancin and Related Glycopeptide Antibiotics,”FEMS Microbiology Reviews26:511-532.
Anderegg, T.R. et al. (2003). “Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity,”J. Clin. Microbiol. 41(6):2795-2796.
Anderegg, T.R. et al. (2003). “Multicenter Quality Control Evaluation Results for Dalbavancin (BI 397), An Investigational Glycopeptide with Potent Gram-Positive Activity,”ASMMay 2003,Poster No. A-090, one page.
Arimoto, H. et al. (1999). “Multi-Valent Polymer of Vancomycin: Enhanced Antibacterial Activity Against VRE,”Chem. Commun. 1999:1361-1362.
Arimoto, H. et al. (2001). “Affinity of a Vancomycin Polymer with Bacterial Surface Models,”Tetrahedron Letters42:3347-3350.
Arioli, V. et al. (1976). “Gardimycin, A New Antibiotic From Actinoplanes: III. Biological Properties,”Journal of Antibiotics29(5):511-515.
Arthur, M. and Courvalin, P. (1993). “Genetics and Mechanisms of Glycopeptide Resistance in Enterococci,”Antimicrobial Agents and Chemotherapy37(8):1563-1571.
Author unknown. (2001). “Dalbavancin tested for soft tissue infections,” located at <http://www.qxhealth.com
ews—archieve/cfml/search—details.cfm?sum—ID=8777> last visited on Sep. 8, 2003, one page.
Author unknown. (2000). “Molecule of the Month V-Glycopeptide,” located at <http://www.prous.com/mom
ov—00/mom.html> last visited on Aug. 27, 2002, two pages.
Author unknown. (2002). “Dalbavancin: The Staph Drug,” located at <http://www.versicor.com/products/dalbava.html> last visited on Aug. 27, 2002, one page.
Author unknown. (2002). “Treatment Hope for Bloodstream Infections Introduced in Five Percent of Intravenous Catheter Cases,” www.biosearch.it, one page.
Barna, J.C.J. and Williams, D.H. (1984). “The Structure and Mode of Action of Glycopeptide Antibiotics of the Vancomycin Group,”Ann. Rev. Microbiol. 38:339-357.
Biavasco, F. et al. (2000). “Glycopeptide Susceptibility Profiles ofStaphylococcus haemolyticusBloodstream Isolates,”Antimicrobial Agents and Chemotherapy44(11): 3122-3126.
Campbell, K.C.M. et al. (2003). “Audiologic Monitoring for Potential Ototoxicity in a Phase I Clinical Trial of a New Glycopeptide Antibiotic,”J. Amer. Acad. Audiology. 14(3):157-168.
Candiani, G. et al. (1999). “In-Vitro and In-Vivo Antibacterial Activity of BI 397, a New Semi-Synthetic Glycopeptide Antibiotic,”J. Antimicrob. Chemother. 44:179-192.
Cavaleri, M. et al. (2002). “Protein Binding of Dalbavancin Using Isothermal Titration Microcalorimetry,”42nd ICAAC Abstracts, San Diego, CA, Sep. 27-30, 2002. Abstract No. A-1385, p. 18.
Cavaleri, M. et al. (2002). “Protein Binding of Dalbavancin Using Isothermal Titration Microcalorimetry,”42nd ICAAC, San Diego, CA, Sep. 27-30, 2002.Poster No. A-1385, one page.
Chaix, C. et al. (1999). “Control of Endemic Methicillin-ResistantStaphylococcus aureus,” JAMA282(18):1745-1751.
Crowe, M. et al. (1998). “Bacteraemia in the Adult Intensive Care Unit of a Teaching Hospital in Nottingham, UK, 1985-1996,”Eur. J. Microbiol. Infect. Dis. 17: 377-384.
Darouiche, R.O. and Mansouri, D.M. (Date Unknown). “Dalbavancin Versus Vancomycin for Prevention ofStaphylococcus aureusColonization of Devices in an Animal Model,”Poster #174, one page.
Dorr, M.B. et al. (2002). “Rationale for Once Weekly Dosing of Dalbavancin, a New Semisynthetic Glycopeptide,”Abstracts of the IDSA 40th Annual Meeting, Oct. 24-27, 2002. Abstract No. 52, p. 53.
Dorr, M.B. et al. (2002). “Rationale for Once Weekly Dosing of Dalbavancin, a New Semisynthetic Glycopeptide,”Abstracts of the IDSA 40th Annual Meeting, Oct. 24-27, 2002.Poster No. 52, one page.
Dowell, J. et al. (2003). “Dalbavancin Dosage Adjustments Not Required for Patients with
Cavaleri Marco
Henkel Timothy
Jabes Daniela
Malabarba Adriano
Mosconi Giorgio
Benson Gregg C.
Forman Frank W.
Peselev Elli
Vicuron Pharmaceuticals Inc.
LandOfFree
Stable pharmaceutical compositions of dalbavancin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable pharmaceutical compositions of dalbavancin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable pharmaceutical compositions of dalbavancin and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3656277